The raise will support Rivermark’s pivotal trial, while allowing the medtech company to ready its FloStent system for commercialisation.

The "Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market" report has been added to Research and Markets' offering. This analysis includes a discussion of products, competitors, ...

ProUroCare Medical, Inc., of Minneapolis, Minn., has filed a de novo application with the FDA seeking marketing clearance for its prostate mechanical imaging (PMI) device (ProUroScan). This will allow ...

Less than a week after making a regulatory submission for a $1 million capital raise, prostate health company ProUroCare Medical, based in Eden Prairie, Minnesota, announced that it has secured market ...

Transrectal ultrasound guided (TRUS) biopsy has been the gold standard for prostate cancer diagnosis, but carries a significant risk of urinary tract infection, sometimes requiring hospital admission ...

The US Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) issued draft guidance Tuesday to support clinical testing of high-intensity ultrasound systems for ...

Because treatment of the whole prostate can lead to long-term side effects in patients with prostate cancer, interest in minimally invasive, focal treatment options has been growing for certain ...